Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastomaJiaji Mao, Jianing Li, Junwei Chen, Qin Wen, Minghui Cao, Fang Zhang, Baoxun Li, Qinyuan Zhang, Zhe Wang, Jingzhong Zhang, Jun Shen
6 December 2023
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomasFuliang Chu, Jingjing Cao, Jingwei Liu, Haopeng Yang, Timothy J Davis, Shao-qing Kuang, Xiaoyun Cheng, Zheng Zhang, Swathi Karri, Long T Vien, Laura Bover, Ryan Sun, Francisco Vega, Michael Green, Richard Eric DavisSee the full list of authors
24 November 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesWilliam C Temple, Matthew A Nix, Akul Naik, Adila Izgutdina, Benjamin J Huang, Gianina Wicaksono, Paul Phojanakong, Juan Antonio Camara Serrano, Elizabeth P Young, Emilio Ramos, Fernando Salangsang, Veronica Steri, Simayijiang Xirenayi, Michelle Hermiston, Aaron C LoganSee the full list of authors
24 November 2023
CD8 chimeric antigen receptor T cells manufactured in absence of CD4 cells exhibit hypofunctional phenotypeSang Yun Lee, Dong Hoon Lee, Wei Sun, Francisco Cervantes-Contreras, Ryan S Basom, Feinan Wu, Si Liu, Richa Rai, Hamid R Mirzaei, Shyril O’Steen, Damian J Green, Mazyar Shadman, Brian G Till
20 November 2023
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancerEls M E Verdegaal, Saskia J Santegoets, Marij J P Welters, Linda de Bruin, Marten Visser, Caroline E van der Minne, Pita M de Kok, Nikki M Loof, Sanne Boekestijn, Inge Roozen, Inge M Westra, Pauline Meij, Sjoerd H Van der Burg, Judith R Kroep
10 November 2023
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Christina Quell, Veit Bücklein, Maria Ingenerf, Marcus Unterrainer, Christian Schmidt, Franziska J Dekorsy, Peter Bartenstein, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Wolfgang G Kunz
25 October 2023
Neoantigen-specific CD4 tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake CeccarelliSee the full list of authors
6 October 2023
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survivalVedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart, Harry Dolstra, Martin A Pule, Claire Roddie
13 September 2023
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cellsKaren Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
7 September 2023
Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune responseYi-Na Wang, Yuan-Yuan Wang, Jin Wang, Wen-Juan Bai, Nai-Jun Miao, Jing Wang
31 August 2023